IDO1 and neoplasm: As noted by Ninomiya et al., preconditioning lymphodepleting chemotherapy before anti-CD19 CAR T infusion (e.g., fludarabine and cyclophosphamide administration) altered tumor immunosuppressive milieu by suppressing IDO expression, which in turn, enhanced the activity of infused cells against IDO positive cancer cells [137].